As a non-invasive way to obtain tumor samples, liquid biopsy has the advantages of minimal invasiveness and repeatability. Through liquid biopsy, corresponding circulating tumor DNA can be obtained, including point mutations, copy number variations, and DNA methylation. It has been approved for the diagnosis and treatment of various malignant tumors. This article reviews the research and application of circulating tumor DNA, a liquid biopsy technology, in the early diagnosis, risk assessment of recurrence and metastasis, treatment guidance, and dynamic follow-up and monitoring of gynecological malignancies.